Skye Bioscience, Inc. financial data

Symbol
SKYE on Nasdaq
Industry
Pharmaceutical Preparations
Location
11250 El Camino Real, Suite 100, San Diego, CA
State of incorporation
Nevada
Fiscal year end
December 31
Former names
Emerald Bioscience, Inc. (to 1/7/2021), Nemus Bioscience, Inc. (to 3/14/2019), LOAD GUARD LOGISTICS, INC. (to 10/30/2014), LOAD GUARD TRANSPORTATION, INC. (to 11/7/2012)
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 361 % +653%
Debt-to-equity 38.6 %
Return On Equity -112 % -125%
Return On Assets -80.7 % +82.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30.3M shares -96.9%
Common Stock, Shares, Outstanding 28.1M shares -97.1%
Entity Public Float 20.4M USD +17.5%
Common Stock, Value, Issued 28.1K USD -97.1%
Weighted Average Number of Shares Outstanding, Basic 38.7M shares +895%
Weighted Average Number of Shares Outstanding, Diluted 38.7M shares +895%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.29M USD +52.2%
General and Administrative Expense 13.3M USD +129%
Operating Income (Loss) -43.3M USD -139%
Nonoperating Income (Expense) 1.07M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -42.3M USD -98.6%
Income Tax Expense (Benefit) 10.1K USD +124%
Net Income (Loss) Attributable to Parent -42.3M USD -98.6%
Earnings Per Share, Basic -3.58 USD/shares +67.2%
Earnings Per Share, Diluted -3.58 USD/shares +67.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 74.1M USD +13293%
Cash, Cash Equivalents, and Short-term Investments 0 USD
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Other Assets, Current 2.71M USD +154%
Assets, Current 87M USD +4497%
Property, Plant and Equipment, Net 45.8K USD -28.9%
Operating Lease, Right-of-Use Asset 203K USD -25%
Other Assets, Noncurrent 8.31K USD 0%
Assets 87.3M USD +3803%
Accounts Payable, Current 1.08M USD -30.4%
Employee-related Liabilities, Current 557K USD -39.1%
Liabilities, Current 14.3M USD +45.9%
Operating Lease, Liability, Noncurrent 130K USD -37.7%
Liabilities 14.5M USD +44.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -117M USD -56.4%
Stockholders' Equity Attributable to Parent 72.8M USD
Liabilities and Equity 87.3M USD +3803%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.71M USD -15.9%
Net Cash Provided by (Used in) Financing Activities 85.7M USD
Net Cash Provided by (Used in) Investing Activities 1.14M USD -79.4%
Common Stock, Shares Authorized 100M shares -98%
Common Stock, Shares, Issued 28.1M shares -97.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 82.1M USD +5664%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 83.2M USD +14810%
Interest Paid, Excluding Capitalized Interest, Operating Activities 126K USD +2848%
Deferred Tax Assets, Valuation Allowance 66.5M USD +51.2%
Deferred Tax Assets, Gross 66.5M USD +51.3%
Operating Lease, Liability 243K USD +209%
Depreciation 27.6K USD -16.9%
Payments to Acquire Property, Plant, and Equipment 3.18K USD +71%
Lessee, Operating Lease, Liability, to be Paid 300K USD +261%
Operating Lease, Liability, Current 79.2K USD +21%
Lessee, Operating Lease, Liability, to be Paid, Year Two 106K USD +27.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 103K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure +25%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 57.1K USD +1199%
Lessee, Operating Lease, Liability, to be Paid, Year Three 90.8K USD
Deferred Tax Assets, Operating Loss Carryforwards 40.9M USD +33.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200K shares -99.6%
Unrecognized Tax Benefits 6.43M USD +124%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 50K USD +234%
Share-based Payment Arrangement, Expense 5.06M USD +802%
Interest Expense 1.32M USD +173%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%